Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FIP1L1::PDGFRA status confers therapeutic sensitivity to Imatinib in patients with Chronic Eosinophilic Leukemia, NOS.
Health Canada approved imatinib mesylate for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.
This statement is based on a regulatory approval from the Health Canada:
GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.